Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
Globe Newswire•11/11/2026•08:00 ET
0
Key Highlights
- ➤Humacyte’s ATEV featured in five presentations at VEITHsymposium November 17-21, 2026
- ➤Company slated to submit Supplemental BLA for hemodialysis AV access in November
- ➤ATEV data include interim Phase 3 results in women receiving hemodialysis
- ➤Integrated durability and safety outcomes span three Phase 3 randomized trials
- ➤Symvess podium presentation will update military and civilian vascular trauma results
Expert Statements
Laura Niklason, Founder, President and Chief Executive Officer of Humacyte
“Vascular surgeons create dialysis access and repair arteries in some of the most challenging settings, and VEITH puts our data in front of the people who make those decisions. These presentations bring together interim Phase 3 results in women, integrated safety and durability outcomes across three Phase 3 trials, evidence of low atherogenic remodeling from ATEVs that remained in patients long-term, and an update from the trauma surgeons who have used Symvess in military and civilian settings.”
– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data.
– Podium presentation to provide an update on clinical results with Symvess® in military and civilian trauma settings.
Get started
Create a free account to read the full story.